Kerrigan J - Search Results

1

Tedeschi PM, Scotto KW, Kerrigan J, Bertino JR. Tedeschi PM, et al. Among authors: kerrigan j. Oncotarget. 2016 Feb 16;7(7):7368-9. doi: 10.18632/oncotarget.7147. Oncotarget. 2016. PMID: 26848977 Free PMC article. No abstract available.

2

Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development.

Tedeschi PM, Vazquez A, Kerrigan JE, Bertino JR. Tedeschi PM, et al. Mol Cancer Res. 2015 Oct;13(10):1361-6. doi: 10.1158/1541-7786.MCR-15-0117. Epub 2015 Jun 22. Mol Cancer Res. 2015. PMID: 26101208 Free PMC article.

3

Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer.

Shaik T, Rather GM, Bansal N, Minko T, Garbuzenko O, Szekely Z, Abali EE, Banerjee D, Kerrigan JE, Scotto KW, Bertino JR. Shaik T, et al. Oncotarget. 2018 Sep 7;9(70):33249-33257. doi: 10.18632/oncotarget.26064. eCollection 2018 Sep 7. Oncotarget. 2018. PMID: 30279956 Free PMC article.

4

A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts.

Xie X, Bansal N, Shaik T, Kerrigan JE, Minko T, Garbuzenko O, Abali EE, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR. Xie X, et al. Oncotarget. 2014 Feb 28;5(4):901-7. doi: 10.18632/oncotarget.1809. Oncotarget. 2014. PMID: 24658650 Free PMC article.

5

Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy.

Tedeschi PM, Lin H, Gounder M, Kerrigan JE, Abali EE, Scotto K, Bertino JR. Tedeschi PM, et al. Mol Pharmacol. 2015 Oct;88(4):720-7. doi: 10.1124/mol.114.096727. Epub 2015 Jul 28. Mol Pharmacol. 2015. PMID: 26219913 Free PMC article.

6

NAD+ Kinase as a Therapeutic Target in Cancer.

Tedeschi PM, Bansal N, Kerrigan JE, Abali EE, Scotto KW, Bertino JR. Tedeschi PM, et al. Clin Cancer Res. 2016 Nov 1;22(21):5189-5195. doi: 10.1158/1078-0432.CCR-16-1129. Epub 2016 Aug 31. Clin Cancer Res. 2016. PMID: 27582489 Review.

7

A second target of benzamide riboside: dihydrofolate reductase.

Roussel B, Johnson-Farley N, Kerrigan JE, Scotto KW, Banerjee D, Felczak K, Pankiewicz KW, Gounder M, Lin H, Abali EE, Bertino JR. Roussel B, et al. Cancer Biol Ther. 2012 Nov;13(13):1290-8. doi: 10.4161/cbt.21786. Epub 2012 Sep 6. Cancer Biol Ther. 2012. PMID: 22954684 Free PMC article.

8

Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.

Hsieh YC, Tedeschi P, Adebisi Lawal R, Banerjee D, Scotto K, Kerrigan JE, Lee KC, Johnson-Farley N, Bertino JR, Abali EE. Hsieh YC, et al. Mol Pharmacol. 2013 Feb;83(2):339-53. doi: 10.1124/mol.112.080218. Epub 2012 Nov 29. Mol Pharmacol. 2013. PMID: 23197646 Free PMC article.

9

Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.

Xie X, Kerrigan JE, Minko T, Garbuzenko O, Lee KC, Scarborough A, Abali EE, Budak-Alpdogan T, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR. Xie X, et al. Cancer Biol Ther. 2013 Aug;14(8):742-51. doi: 10.4161/cbt.25184. Epub 2013 Jun 3. Cancer Biol Ther. 2013. PMID: 23792570 Free PMC article.

10

Functional annotation of rare gene aberration drivers of pancreatic cancer.

Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M, Nair N, Minelli R, Chong Z, Chen F, Chang QE, Dennison JB, Dogruluk A, Li M, Ying H, Bertino JR, Gingras MC, Ittmann M, Kerrigan J, Chen K, Creighton CJ, Eterovic K, Mills GB, Scott KL. Tsang YH, et al. Among authors: kerrigan j. Nat Commun. 2016 Jan 25;7:10500. doi: 10.1038/ncomms10500. Nat Commun. 2016. PMID: 26806015 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

368 results

Search Page

Filters